Last edition
News about "subcutaneous drug delivery innovation"
Amgen Announces Positive Phase 3 Results for TEPEZZA
Amgen reports positive Phase 3 topline results for subcutaneous TEPEZZA in thyroid eye disease, with key endpoints met and 77 percent of patients achieving significant proptosis reduction.
Subcutaneous Drug Delivery Innovation | 07/04/2026 | By News Bureau
Alteogen and Biogen Sign Deal for Hybrozyme-Based Subcutaneous Biologics
Alteogen signs a licensing deal with Biogen to develop and commercialise Hybrozyme-based subcutaneous biologics, granting rights for two products using the ALT-B4 platform.
Subcutaneous Drug Delivery Innovation | 26/03/2026 | By News Bureau | 190
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy